STATERA BIOPHARMA INC - STAB STOCK NEWS

Statera Biopharma (Nasdaq: STAB) has announced a strategic agreement with Immune Therapeutics to sell its rights to naltrexone and met-enkephalin. This deal is expected to strengthen Statera's financial position, potentially generating over $400 million in non-dilutive cash flow through an upfront payment of $2 million, stock equity, and milestone payments. The CEO highlighted that this move will support the development of new product candidates aimed at treating various immune-related diseases.

Statera Biopharma (Nasdaq: STAB) announced it is not in compliance with Nasdaq listing rules due to a delay in filing its Annual Report on Form 10-K for the fiscal year ending December 31, 2021. The company has until June 20, 2022, to submit a compliance plan. Additionally, recent board resignations have left the company with inadequate independent directors, affecting its governance structure. The resignation of its independent auditor, Tuner, Stone & Company, further complicates its financial reporting. Statera is actively seeking a new auditor while working to regain compliance.

Statera Biopharma (Nasdaq: STAB) announced a strategic agreement with Coeptis Therapeutics to sell its rights to Entolimod and related TLR5 agonists. The transaction includes a $6 million upfront payment and milestone payments based on revenue. This move aims to enhance Statera's financial position and support the development of its immunotherapy programs. The sale is contingent on finalizing a definitive agreement and satisfying certain conditions, including financing from Coeptis.

Coeptis Therapeutics has entered into a strategic agreement with Statera Biopharma to acquire its toll-like receptor 5 (TLR5) agonist platform, including the clinical-stage candidate entolimod, for $6 million. The agreement is subject to further negotiation and financing conditions. Entolimod is being developed to treat acute radiation syndrome and has shown potential in treating neutropenia and anemia in cancer patients. This acquisition is expected to enhance Coeptis' pipeline and address underserved medical needs in light of the current geopolitical climate.

Statera Biopharma (Nasdaq: STAB) has filed a Form 12b-25 with the SEC, extending the due date for its Annual Report on Form 10-K for the fiscal year ended December 31, 2021, to April 15, 2022. The delay is attributed to challenges in completing financial statements and audit processes by its independent registered public accounting firm. Consequently, the company has postponed its conference call and webcast that was intended to discuss the financial results for the full year 2021.

Statera Biopharma (Nasdaq: STAB) will host a conference call and audio webcast on March 31, 2022, at 5:30 p.m. ET to discuss its Q4 and full-year financial results for 2021. The event invites stakeholders to hear the latest updates on corporate performance. The call will be accessible via telephone and webcast, with a replay available on their website for 90 days post-event. Statera Biopharma focuses on developing innovative immunotherapies targeting various health issues, including autoimmune diseases and cancers.

Statera Biopharma, Inc. (NASDAQ: STAB) has successfully closed its public offering of 12,555,555 units, raising approximately $5.7 million before expenses. Each unit comprises one share of common stock and two warrants with differing terms—one-year at $0.45 and five-year at $0.5625 per share. The underwriters partially exercised their option to purchase additional warrants. A 45-day option for underwriters to buy up to another 1,883,333 shares at $0.43 is also included. The offering is facilitated under a previously effective shelf registration statement.

Statera Biopharma (NASDAQ: STAB) announced a public offering of approximately 10,843,721 units priced at $0.45 each, and 1,716,666 pre-funded units at $0.44, totaling about $5.7 million in gross proceeds. Each unit includes common stock and warrants with varying terms and exercise prices. Additionally, underwriters have a 45-day option to purchase up to 1,884,057 shares to cover over-allotments. The offering, set to close around March 24, 2022, is conducted under a prior SEC registration statement.

Statera Biopharma (NASDAQ: STAB) announced a public offering of units consisting of common stock and warrants, correcting previous deal terms. The offering is underwritten by EF Hutton and registered under Form S-3 with the SEC. Each unit includes one year and five-year warrants. The preliminary prospectus supplement will be filed today. This offering aims to secure funds for advancing clinical programs targeting autoimmune diseases, cancers, and COVID-19. The company focuses on immune restoration therapies and holds a diverse platform of toll-like receptor agonists.